<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783380</url>
  </required_header>
  <id_info>
    <org_study_id>KEK No 805 (EK 151/03)</org_study_id>
    <nct_id>NCT00783380</nct_id>
  </id_info>
  <brief_title>Influenza Vaccination in Immunocompromized Patients</brief_title>
  <official_title>Double Blind Randomized Comparison of a Subunit- and a Virosomal Influenza Vaccine in Immunocom-Promized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the immunogenicity and reactogenicity of two different formulations of
      commercially avail-able influenza vaccines in 4 different groups of immunocompromized
      outpatients (HIV positive patients, patients suffering from rheumatologic diseases and
      receiving treatment with immunosuppressive drugs and patients undergoing hemodialysis or
      continuous ambulatory peritoneal dialysis). The aim of the study was to investigate if the
      newest formulation of influenza vaccines (virosomal vaccines) offer a benefit in
      immunocompromized patients in comparison to an older subunit formulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The infection with influenza is associated with higher morbidity and mortality in risk groups
      including immunocompromized patients. The virosomal influenza vaccines have been associated
      with improved immunogenicity in former trials. No direct comparison with older formulations
      has been conducted so far.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity defined as seroconversion (1:&gt;=4) and seroprotection rates (1:&gt;=40)</measure>
    <time_frame>&gt;60 Wochen</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity in rheumatologic patients by disease specific scores</measure>
    <time_frame>Six weeks after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate side effects at time of application of vaccination</measure>
    <time_frame>Minutes after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects after vaccination</measure>
    <time_frame>First week after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Virosomal influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Subunit influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Virosomal influenza vaccine</intervention_name>
    <description>Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients</description>
    <arm_group_label>Virosomal influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Subunit influenza vaccine</intervention_name>
    <description>Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients</description>
    <arm_group_label>Subunit influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult outpatients treated at the Inselspital Bern for:

          -  HIV infection

          -  rheumatologic diseases and receiving immunosuppressive drugs

          -  kidney transplant recipients

          -  undergoing hemodialysis or continuous ambulatory peritoneal dialysis

          -  written informed consent

        Exclusion Criteria:

          -  Allergy to egg proteins

          -  Former adverse reactions to prior vaccination

          -  Febrile conditions at the time of study inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Evison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, University Hospital Bern, 3010-Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology/Hypertension, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatic Diseases, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Vilchez RA, Fung J, Kusne S. The pathogenesis and management of influenza virus infection in organ transplant recipients. Transpl Infect Dis. 2002 Dec;4(4):177-82. Review.</citation>
    <PMID>12535259</PMID>
  </reference>
  <reference>
    <citation>Bridges CB, Fukuda K, Cox NJ, Singleton JA; Advisory Committee on Immunization Practices. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2001 Apr 20;50(RR-4):1-44.</citation>
    <PMID>11334444</PMID>
  </reference>
  <reference>
    <citation>Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 1994 Apr;8(4):469-76.</citation>
    <PMID>7912086</PMID>
  </reference>
  <reference>
    <citation>Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS. 1997 Dec;8(12):776-9.</citation>
    <PMID>9433953</PMID>
  </reference>
  <reference>
    <citation>Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, Teufel A. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol. 1994 Jul;21(7):1203-6.</citation>
    <PMID>7966058</PMID>
  </reference>
  <reference>
    <citation>Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002 Dec;29(12):2555-7.</citation>
    <PMID>12465151</PMID>
  </reference>
  <reference>
    <citation>Cavdar C, Sayan M, Sifil A, Artuk C, Yilmaz N, Bahar H, Camsari T. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol. 2003;37(1):71-6.</citation>
    <PMID>12745749</PMID>
  </reference>
  <reference>
    <citation>Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B, Gl√ºck R, Cryz SJ Jr. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. 1997 Oct;15(15):1675-9.</citation>
    <PMID>9364699</PMID>
  </reference>
  <reference>
    <citation>Baldo V, Menegon T, Bonello C, Floreani A, Trivello R; Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine. 2001 May 14;19(25-26):3472-5.</citation>
    <PMID>11348713</PMID>
  </reference>
  <reference>
    <citation>Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002 Dec 20;20 Suppl 5:B29-32. Review.</citation>
    <PMID>12477415</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>October 31, 2008</last_update_submitted>
  <last_update_submitted_qc>October 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Evison John, MD Oberarzt</name_title>
    <organization>Universit√§tsklinik f√ºr Infektiologie, PKT 2B, Inselspital, 3011 Bern, Switzerland</organization>
  </responsible_party>
  <keyword>Influenza vaccination</keyword>
  <keyword>Subunit</keyword>
  <keyword>Virosomal</keyword>
  <keyword>HIV/AIDS</keyword>
  <keyword>Renal Dialysis</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Rheumatologic diseases</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Reactogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

